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S U M M A R Y
Data evaluating the screening practices for viral hepatitides and sexually transmitted infections (STIs) in
patients presenting for non-occupational HIV post-exposure prophylaxis (nPEP) care are limited.
Screening practices and prevalences of viral hepatitides and STIs were evaluated in 126 patients
presenting to a dedicated HIV prevention clinic for HIV nPEP. Three patients (2.4%) were diagnosed with
chronic hepatitis C infection, 28 (22.2%) did not have surface antibodies in sufﬁcient quantity to confer
immunity to hepatitis B, and six (4.8%) were diagnosed with an STI. A multivariate regression model did
not predict any demographic or clinical features predictive of HBV non-immunity. Beyond screening for
HIV infection, evaluation for viral hepatitides and STIs is an important feature in the care of patients
presenting for HIV nPEP.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Individuals presenting for HIV non-occupational post-expo-
sure prophylaxis (nPEP) are at risk of acquiring concomitant
infections via sexual contact or percutaneous exposures, includ-
ing sexually transmitted infections (STIs), hepatitis B (HBV), and
hepatitis C (HCV). Little is known about the infectious comorbid-
ities of patients presenting for nPEP at baseline, and although
published guidelines recommend screening for co-infections,1,2
the frequency with which screening occurs in real-world settings
is unclear.
2. Methods
This prospective cohort study was conducted at the HIV
Prevention Clinic at the Toronto General Hospital between January* Corresponding author. Fax: +1 (416) 340 3357.
E-mail address: isaac.bogoch@uhn.ca (I.I. Bogoch).
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1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1, 2013 and September 30, 2014, and was approved by the
University Health Network (UHN) Research Ethics Board. All
patients enrolled in this study underwent a structured clinical
evaluation. STIs (syphilis, chlamydia, and gonorrhea) were
routinely screened for and treated as per the current Public Health
Agency of Canada STI Guidelines.3 Screening speciﬁcally included
urine PCR for chlamydia and gonorrhea infections, and rectal and
oral swabs for chlamydia and gonorrhea culture. Additionally, we
attempted to screen all patients for HCV antibodies at baseline and
for up to 6 months at follow-up appointments after any sexual or
percutaneous exposure. Patients were also screened for HBV
immunity with a surface antibody (HBsAb) test at baseline.
Patients with high-risk HBV exposures were managed as per
clinical guidelines.4 HBV surface antibody production was
conﬁrmed following completion of the vaccine series or booster
immunization in those who followed up to clinic.
All clinical data were transferred from a structured dictated
note into a prospectively designed database. All analyses were
conducted using IBM SPSS version 22.0 software (IBM, Armonk, NY,
USA). Signiﬁcance was deﬁned at p < 0.05. Fisher’s exact t-test wasciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
N. Sivachandran et al. / International Journal of Infectious Diseases 40 (2015) 142–144 143used for 2  2 comparisons. Multivariable logistic regression was
used in adjusted comparisons of HBV immunity.
3. Results
One hundred twenty-six patients attended the HIV Prevention
Clinic for nPEP care between January 1, 2013 and September 30,
2014. One hundred nineteen of these 126 patients (94.4%) had
clear knowledge and documentation of the type, route, and source
of potential HIV exposure. Of these 119, there were 83 (69.7%)
sexual exposures and 36 (30.3%) non-sexual exposures. Of the
126 patients who presented for their initial nPEP clinic appoint-
ment, 96 (76.2%) were male; 115 (91.3%) were screened for HBV
infection and immunity and 111 (88.1%) were screened for
hepatitis C. Ninety-six of the total patients (76.2%) were screened
for at least one STI, which included 81 of 83 (97.6%) patients
presenting with sexual exposures. None of the patients serocon-
verted with HIV.
Table 1 outlines the infectious diagnoses in those presenting for
HIV nPEP. All infected individuals were male. Over the course of
this study there were no cases of HCV seroconversion, however
three cases (2.4% prevalence) of chronic HCV infection were
identiﬁed. Six patients (4.8%) were diagnosed with an STI at their
initial clinic visit. Twenty-eight patients (22.2%) did not have
HBsAb at a level conferring immunity. Fifteen (53.6%) HBV non-
immune patients were retained in care long enough to either
complete the HBV vaccine series or obtain a booster vaccination
dose and document HBsAb seroconversion. A multivariate logistic
regression analysis demonstrated that increasing age (adjusted
odds ratio (AOR) per additional year 1.01, 95% conﬁdence interval
(CI) 0.96–1.05), female sex (AOR 1.13, 95% CI 0.36–3.69), non-
white race (AOR 1.95, 95% CI 0.77–4.92), and increasing number of
high-risk sexual exposures (AOR per sexual exposure 0.72, 95% CI
0.48–1.08) were not signiﬁcantly associated with HBV non-
immunity after adjusting for age, sex, race, and number of sexual
exposures.
4. Discussion
Screening for STIs, HCV, and HBV is important in the care of
individuals seeking HIV nPEP. The present ﬁndings support current
guidelines for the routine screening of STIs, HCV, and HBV in
patients presenting for HIV nPEP.1,2 Most published studies
examining patients presenting for HIV nPEP have traditionallyTable 1
Results of screening for hepatitis B, hepatitis C, and STIs in 119 patients presenting
for HIV nPEP
Sexual exposures,
n (%)
(n = 83)
Non-sexual exposures,
n (%)
(n = 36)
Hepatitis B
Immune 60 (69.8) 22 (61.1)
Not immune 15 (18.1) 13 (36.1)
Not tested 8 (9.6) 1 (2.8)
Hepatitis C
Positive 2 (2.4) 1 (2.8)
Negative 72 (86.7) 31 (86.1)
Not tested 9 (10.8) 4 (11.1)
STI diagnosis
No STI 74 (89.2) 12 (33.3)
Chlamydia 3 (3.6) 1 (7.7)
Gonorrhea 1 (1.2) 0 (0)
Syphilis 1 (1.2) 0 (0)
Not tested 4 (4.8) 23 (63.9)
STI, sexually transmitted infection; HIV nPEP, non-occupational HIV post-exposure
prophylaxis.focused on measuring adherence to medications or clinic visits,
and on HIV seroconversion rather than reporting on the screening
or treatment of potential co-infections.5–7 Additionally, those
individuals diagnosed with bacterial STIs in nPEP settings may be
good candidates for HIV pre-exposure prophylaxis (PrEP).8,9 This
study provides evidence that such screening is valuable and that
practitioners should be vigilant about investigating for these
potentially transmissible infections.
The study clinic has redundancies designed to increase the
probability of testing for co-infections. Protocols have been
designed to ensure that patients referred to the HIV Prevention
Clinic undergo baseline screening in participating emergency
departments (EDs), the most common initial point of patient
contact. This mechanism allows for laboratory results to be
available to healthcare providers at the time the patient is
evaluated in the HIV Prevention Clinic 3 days later.
An important area for quality improvement identiﬁed in this
study is ensuring that patients who are not immune to HBV either
(1) complete the vaccine series if they have no prior history of
vaccination, or (2) receive a booster vaccination if they have a
history of vaccination, and (3) all have documentation of HBV
surface antibodies following vaccination.10 Ensuring HBV immu-
nity post vaccination is often quite challenging given major issues
with adherence, both to medications and clinic attrition in nPEP
care,5–7,11–13 and completing a vaccination series for HBV
typically involves follow-up over a 6-month time period.
Strategies such as automated reminders should be optimized to
ensure appropriate vaccination protocols are undertaken to
immunize individuals.
Weaknesses of this study include the lack of screening and
vaccination for hepatitis A infection, human papillomavirus, and
pregnancy screening. In addition, the data presented are only
reﬂective of patients referred to this clinic from three EDs and
several local clinics, and may not be reﬂective of the unique
demographics in other settings. Lastly, these data would be more
robust if they could be compared to screening rates prior to the
establishment of the dedicated HIV Prevention Clinic and
implementation of screening protocols.
The present ﬁndings support current recommendations for
universal screening for viral hepatitis and STIs among patients
presenting for HIV nPEP care.
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